Provided by Tiger Trade Technology Pte. Ltd.

TG Therapeutics

53.86
-1.5300-2.76%
Volume:562.14K
Turnover:30.72M
Market Cap:8.25B
PE:19.45
High:56.26
Open:55.71
Low:53.78
Close:55.39
52wk High:59.30
52wk Low:26.76
Shares:153.09M
Float Shares:141.54M
Volume Ratio:0.68
T/O Rate:0.40%
Dividend:- -
Dividend Rate:- -
EPS(TTM):2.77
EPS(LYR):2.77
ROE:100.28%
ROA:7.28%
PB:13.65
PE(LYR):19.44

Loading ...

TG Therapeutics to host conference call on first-quarter results and 2026 outlook

Reuters
·
Apr 30

TG Therapeutics Announces Data Presentations for BRIUMVI in Multiple Sclerosis at the American Academy of Neurology 2026 Annual Meeting

GlobeNewswire
·
Apr 22

Goldman Sachs Reaffirms Their Hold Rating on TG Therapeutics (TGTX)

TIPRANKS
·
Apr 16

TG Therapeutics completes enrollment in Phase 3 subcutaneous Briumvi trial in MS

Reuters
·
Apr 15

TG Therapeutics Inc - Top-Line Data From Phase 3 Subcutaneous Briumvi Trial Expected Year-End 2026 or Q1 2027

THOMSON REUTERS
·
Apr 15

Analysts Conflicted on These Healthcare Names: TG Therapeutics (TGTX), Insmed (INSM) and Solventum Corporation (SOLV)

TIPRANKS
·
Apr 08

TG Therapeutics Credit Deal And Valuation Gap Catch Investor Attention

Simply Wall St.
·
Mar 22

TG Therapeutics Files Procedural 8-K on Financial Obligation

TIPRANKS
·
Mar 21

TG Therapeutics enters USD 750 billion term loan amendment with Blue Owl Capital Corporation-led lenders

Reuters
·
Mar 21

BRIEF-TG Therapeutics Secures An Additional $500 Million In Non-Dilutive Capital From Blue Owl And Expands Share Repurchase Program To $300 Million

Reuters
·
Mar 19

TG Therapeutics Inc - Enters Five-Year $750 Mln Credit Facility With Blue Owl Capital

THOMSON REUTERS
·
Mar 19

TG Therapeutics Secures an Additional $500 Million in Non-Dilutive Capital From Blue Owl and Expands Share Repurchase Program to $300 Million

THOMSON REUTERS
·
Mar 19

TG Therapeutics Inc - Increases Share Repurchase Program to $300 Mln

THOMSON REUTERS
·
Mar 19